Enforcement Report - Week of February 7, 2024
ChargePoint and Steris Partner to Provide a Sterile Solution to Evonik
FREDERICK, Md/, Oct. 10, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), today announced that it has recently received a purchase order for an iHP Custom Engineered System (CES) from Avid Bioservices, Inc. (Avid) for implementation in Avid’s new purpose-built viral vector development and manufacturing facility in Costa Mesa, California.
Enforcement Report - Week of July 27, 2022
Enforcement Report - Week of July 20, 2022
LENEXA, Kan., Dec. 9, 2021 /PRNewswire/ -- Public health concerns related to the SARS-CoV-2 virus continue with the Delta variant largely responsible for a rise in cases over the last several months. Synexis® LLC, a pioneer in microbial reduction and sole developer of patented technology that creates Dry Hydrogen Peroxide (DHP™) for occupied spaces, today announced results from new research showing that DHP™ significantly reduces the Delta variant viral load in the air in a sealed test room (total volume 1280 ft3) in 90 minutes. Specifically, aerosolized viral concentrations were reduced below detectable levels, greater than 99.99%, after 90 minutes of DHP™ operation.1 This research reinforces previous Synexis studies demonstrating effectiveness in reducing SARS-CoV-2 and other microbes in various settings.
MALVERN, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) --Â Galera Therapeutics, LLC. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a pilot Phase 2 clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. GC4419 is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen.
Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined.